Advaxis is a clinical stage biotechnology company engaged in the discovery, development and commercialization of proprietary Lm-LLO cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen/adjuvant fusion proteins. The company's Lm-LLO immunotherapy product candidate is ADXS-HPV, which is for the treatment of human papilloma virus. The company's other product includes: ADXS-PSA, which is designed to target the PSA associated with prostate cancer; and ADXS-HER2, which is designed for the treatment of HER2 expressing cancers, including human and canine osteosarcoma.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.